HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by de Keizer, B. Articles by de Klerk, J. M.H. Search for Related Content PubMed PubMed Citation Articles by de Keizer, B. Articles by de Klerk, J. M.H.

Bone Marrow Dosimetry and Safety of High ¹³¹I Activities Given After Recombinant Human Thyroid-Stimulating Hormone to Treat Metastatic Differentiated Thyroid Cancer

¹ Department of Nuclear Medicine, Utrecht University Medical Center, Utrecht, The Netherlands
² Research and Development, Mallinckrodt, Tyco Healthcare, Petten, The Netherlands
³ Department of Nuclear Medicine, Ghent University Hospital, Ghent, Belgium
⁴ Department of Endocrinology, Utrecht University Medical Center, Utrecht, The Netherlands

Recombinant human thyroid-stimulating hormone (rhTSH) recently was introduced as a radioiodine administration adjunct that avoids levothyroxine (LT-4) withdrawal and resultant hypothyroidism. The pharmacokinetics of ¹³¹I after rhTSH administration are known to differ from those after LT-4 withdrawal but are largely nondelineated in the radioiodine therapy setting. We therefore sought to calculate the red marrow absorbed dose of high therapeutic activities of ¹³¹I given after rhTSH administration to patients with metastatic or inoperable locally recurrent differentiated thyroid cancer. We also sought to evaluate the clinical and laboratory effects of this therapy on the bone marrow. Methods: Fourteen consecutive patients received in total 17 ¹³¹I treatments (7.4 GBq). Blood and urine samples were obtained at fixed intervals, and their activities were measured in a well counter. Based on blood activity, renal clearance of the activity, and residence times in red marrow and the remainder of the body, the red marrow absorbed dose was calculated using the MIRD schema. Additionally, we monitored for potential hematologic toxicity and compared platelet counts before and 3 mo after treatment. Results: The mean ± SD absorbed dose per unit of administered ¹³¹I in the red marrow was 0.16 ± 0.07 mGy/MBq. The corresponding total red marrow absorbed dose was 1.15 ± 0.52 Gy (range, 0.28–1.91 Gy). In none of the patients was hematologic toxicity observed. The mean ± SD platelet count (n = 13 treatments) was 243 ± 62 x 10⁹/L before treatment and 233 ± 87 x 10⁹/L 3 mo later, a slight and statistically insignificant decrease. After rhTSH-aided administration of high activities of ¹³¹I, the bone marrow absorbed dose remained under 2 Gy, the level long considered the safety threshold for all radioiodine therapy. Conclusion: Our specific findings imply that when clinically warranted, rhTSH should allow an increase in the therapeutic radioiodine activity. Such an increase might improve efficacy while preserving safety and tolerability; this possibility should be assessed in further studies.

Key Words: thyroid cancer • radioiodine • recombinant thyroid-stimulating hormone • bone marrow dosimetry

Related articles in JNM:

THIS MONTH IN JNM

JNM 2004 45: 8A-9A. [Full Text]  

This article has been cited by other articles:

				A. Frigo, A. Dardano, E. Danese, M. V. Davi, P. Moghetti, C. Colato, G. Francia, F. Bernardi, C. Traino, F. Monzani, et al. Chromosome Translocation Frequency after Radioiodine Thyroid Remnant Ablation: A Comparison between Recombinant Human Thyrotropin Stimulation and Prolonged Levothyroxine Withdrawal J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3472 - 3476. [Abstract] [Full Text] [PDF]

				A. Serna, M. Alcaraz, J. L. Navarro, C. Acevedo, V. Vicente, and M. Canteras Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients Radiat Prot Dosimetry, May 1, 2008; 129(4): 372 - 380. [Abstract] [Full Text] [PDF]

				L. H Duntas and B. Biondi Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences Eur. J. Endocrinol., January 1, 2007; 156(1): 13 - 19. [Abstract] [Full Text] [PDF]

				C. C. Travis and M. G. Stabin 131I Ablation Treatment in Young Females After the Chernobyl Accident J. Nucl. Med., October 1, 2006; 47(10): 1723 - 1727. [Abstract] [Full Text] [PDF]

				H. Hanscheid, M. Lassmann, M. Luster, S. R. Thomas, F. Pacini, C. Ceccarelli, P. W. Ladenson, R. L. Wahl, M. Schlumberger, M. Ricard, et al. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal J. Nucl. Med., April 1, 2006; 47(4): 648 - 654. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				M. Lassmann, H. Hanscheid, C. Reiners, S. R. Thomas, B. de Keizer, J. M.H. de Klerk, and M. W. Konijnenberg Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Differentiated Thyroid Cancer After Stimulation with rhTSH J. Nucl. Med., May 1, 2005; 46(5): 900 - 901. [Full Text] [PDF]

				G. Sgouros Blood and Bone Marrow Dosimetry in Radioiodine Therapy of Thyroid Cancer J. Nucl. Med., May 1, 2005; 46(5): 899 - 900. [Full Text] [PDF]